Emulsion formulations

Abstract

A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and / or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This is a continuation in part of U.S. patent application Ser. No. 12 / 983,216, filed Dec. 31, 2010, which claims the benefit of U.S. Provisional Patent Application No. 61 / 291,769, filed Dec. 31, 2009. The disclosures of the foregoing applications are hereby incorporated herein by reference in their respective entireties, for all purposes.FIELD OF THE INVENTION[0002]The present invention relates generally to self-emulsified, self-micro, and self-nano, drug delivery systems (herein referred to as “SEDDS,”“SMEDDS,” and “SNEDDS,” respectively) of lipophilic drugs containing phytosterols and / or phytosterol fatty acid esters. Further, the present invention relates to such systems containing testosterone and / or testosterone esters for the treatment of testosterone deficiency. Still further, the present invention relates to pharmaceutical composition comprising testosterone undecanoate (TU) and phytosterol fatty acid esters with fast release, enh...

AI Technical Summary

Benefits of technology

This patent is about a new type of drug delivery system that can dissolve in water easily and release the drug quickly. This system can be made into different formulations depending on the needs of the patient. The drug is a type of medication that is commonly solubilized in a liver-based fluid. Overall, this invention allows for the creation of a more effective and efficient way to deliver drugs to patients.

Problems solved by technology

This may result in a lowered systemic bioavailability of the drug as the drug is metabolized.

Poor water solubility is a significant obstacle for drug absorption.

Approximately 40% of drugs worldwide are insoluble in water and therefore, are difficult to formulate.

First, poor water solubility can limit the type of formulation available to a bioactive compound.

Second, poorly soluble compounds are likely to have limited bioavailability because once in the body, they do not remain in solution at the site of action.

This results in lower absorption and reduced efficacy.

However, higher doses can potentially lead to increased side effects.

The particle size reduction technologies often fail to overcome bioavailability limitations and result in a large food effect, i.e., much higher exposure in a fed state than in a fasted state, which can lead to greater sensitivity of the pharmacokinetic profile to the fat content of meals and the timing of food administration.

These conventional dissolution enhancement and transient solubilization technologies do not improve the transport across the unstirred water (or boundary) layer (UWL), which separates the bulk fluid phase of the small intestine lumen from the brush border membrane of enterocytes.

For many poorly soluble drugs, this transport across the UWL represents the dominant rate-limiting step for drug absorption.

However, the selection of the formulation components and their relative quantities in the formulation is unpredictable.

Oral, and transdermal administration is particularly challenging because testosterone is metabolized by 5-alpha reductase enzyme in the skin or GI brush-border layer to dihydrotestosterone resulting in supraphysiological levels of DHT.

For the Andriol® Testocaps®, however, there is little to no drug released (1%) for the entire 4 hours.

Drawbacks of the aforementioned therapies are as follows: 1) the therapies can have a too short effect on the systemic testosterone level, with a rapid decrease in the level shortly after an increase resulting from an oral administration; 2) the therapies' lack of individual time control of the testosterone action (in the case of i.m. injection of testosterone esters) due to the inability to change the constantly set testosterone level over a long period of time (days to weeks to months); 3) the presence of a significant food effect upon oral administration; 4) the elevation of DHT levels above physiological normal levels due to the metabolism of testosterone and its esters in organs with high 5-α-reductase activity and 5) where the therapies are in gel form, they may be hazardous to children or others, e.g., where a third party comes in contact with the skin after topical administration.

Despite the promise shown by some of the recent SEDDS formulation of testosterone undecanoate reported in above patent applications, no oral testosterone replacement therapy has yet been approved by FDA.

Images